Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib (Q34847583)

4 August 2017

1 reference

title

Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib (English)

1 reference

4 August 2017

1 reference

1 reference

Jody K Takemoto

1

1 reference

4 August 2017

Jonathan K Reynolds

2

1 reference

4 August 2017

Connie M Remsberg

3

1 reference

4 August 2017

Karina R Vega-Villa

4

1 reference

4 August 2017

Neal M Davies

5

1 reference

4 August 2017

1 January 2008

1 reference

Clinical Pharmacokinetics

4 August 2017

1 reference

4 August 2017

47

1 reference

4 August 2017

11

1 reference

4 August 2017

703-720

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200847110-00002

4 August 2017

0 references

cites work

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

1 reference

12 December 2020

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

1 reference

12 December 2020

Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor

1 reference

12 December 2020

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

1 reference

12 December 2020

Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans

1 reference

12 December 2020

High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluo

1 reference

12 December 2020

Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

1 reference

12 December 2020

Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection

1 reference

12 December 2020

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications

1 reference

12 December 2020

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

1 reference

12 December 2020

Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices

1 reference

12 December 2020

The analgesic effect of etoricoxib relative to that of cetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain

1 reference

12 December 2020

Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet

1 reference

12 December 2020

Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?--Not as easy as 1, 2, 3.

1 reference

12 December 2020

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib

1 reference

12 December 2020

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

1 reference

12 December 2020

Effects of etoricoxib on the pharmacokinetics of phenytoin.

1 reference

12 December 2020

Determination of etoricoxib in human plasma by liquid chromatography–tandem mass spectrometry with electrospray ionisation

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

1 reference

12 December 2020

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat

1 reference

12 December 2020

Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations

1 reference

12 December 2020

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

1 reference

12 December 2020

Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations

1 reference

12 December 2020

Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique

1 reference

12 December 2020

Efficacy of the newest COX-2 selective inhibitors in rheumatic disease

1 reference

12 December 2020

In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions

1 reference

12 December 2020

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

1 reference

12 December 2020

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

12 December 2020

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.

1 reference

12 December 2020

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

12 December 2020

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

1 reference

12 December 2020

Global gastrointestinal safety profile of etoricoxib and lumiracoxib

1 reference

12 December 2020

Celecoxib inhibits 5-lipoxygenase

1 reference

12 December 2020

Toxicokinetics of indomethacin-induced intestinal permeability in the rat

1 reference

12 December 2020

Isolation and structural characterization of the photolysis products of etoricoxib.

1 reference

12 December 2020

A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model

1 reference

12 December 2020

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

1 reference

12 December 2020

Pharmacokinetics of etoricoxib in patients with renal impairment

1 reference

12 December 2020

A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma

1 reference

12 December 2020

Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction

1 reference

12 December 2020

Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat

1 reference

12 December 2020

Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS.

1 reference

12 December 2020

COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

12 December 2020

Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol

1 reference

12 December 2020

Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study

1 reference

12 December 2020

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

1 reference

12 December 2020

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

12 December 2020

The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin

1 reference

12 December 2020

Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site

1 reference

12 December 2020

Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal

1 reference

12 December 2020

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

1 reference

12 December 2020

The pharmacology of selective inhibition of COX-2

1 reference

12 December 2020

Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib

1 reference

12 December 2020

Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

1 reference

12 December 2020

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

1 reference

12 December 2020

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

1 reference

12 December 2020

Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach

1 reference

12 December 2020

Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib

1 reference

12 December 2020

In-line measurement of a drug substance via near infrared spectroscopy to ensure a robust crystallization process

1 reference

12 December 2020

Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

1 reference

12 December 2020

Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors

1 reference

12 December 2020

The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial

1 reference

12 December 2020

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis

1 reference

12 December 2020

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

1 reference

12 December 2020

The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.

1 reference

12 December 2020

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

Characterization of etoricoxib, a novel, selective COX-2 inhibitor

1 reference

12 December 2020

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

10.2165/00003088-200847110-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference